Table 4 Relationships between primary endpoints and secondary endpoints
| Â | Trials with severe patients | Trials with non-severe patients | ||||
|---|---|---|---|---|---|---|
Primary endpoints | Primary endpoints | |||||
Improvementa (N=45) | Worseninga (N=39) | Unknowna (N=13) | Improvementa (N=97) | Worseninga (N=117) | Unknowna (N=51) | |
Secondary endpoints | ||||||
Binary | ||||||
 Improvement | 18 (40.0%) | 7 (17.9%) | 13 (100.0%) | 29 (29.9%) | 28 (23.9%) | 8 (15.7%) |
 Recovery | 3 (6.7%) | 2 (5.1%) | 13 (100.0%) | 5 (5.2%) | 2 (1.7%) | 51 (100.0%) |
 Mortality | 27 (60.0%) | 26 (66.7%) | 4 (30.8%) | 43 (44.3%) | 49 (41.9%) | 24 (47.1%) |
Time-to-event | ||||||
 Improvement | 20 (44.4%) | 14 (35.9%) | 5 (38.5%) | 29 (29.9%) | 31 (26.5%) | 8 (15.7%) |
 Recovery | 3 (6.7%) | 4 (10.3%) | 2 (15.4%) | 8 (8.2%) | 5 (4.3%) | 4 (7.8%) |
 Mortality | 7 (15.6%) | 9 (23.1%) | 3 (23.1%) | 10 (10.3%) | 12 (10.3%) | 5 (9.8%) |
Ordinal | ||||||
 One time point | 9 (20.0%) | 6 (15.4%) | 2 (15.4%) | 10 (10.3%) | 20 (17.1%) | 6 (11.8%) |
 Longitudinal | 7 (15.6%) | 10 (25.6%) | 1 (7.7%) | 7 (7.2%) | 12 (10.3%) | 2 (3.9%) |